A Phase II, Randomized, Open-Label Study Evaluating The Antitumor Activity Of MEDI-522, A Humanized Monoclonal Antibody Directed Against The Human Alpha V Beta 3 Integrin, ± Dacarbazine In Patients With Metastatic Melanoma
This is a Phase II, randomized, open-label, two-arm, multicenter study of MEDI 522 ± DTIC in
previously untreated (other than adjuvant immunotherapy) patients with Stage IV metastatic
melanoma (AJCC staging).
Interventional
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Explore antitumor activity of MEDI-522 in patients with metastatic melanoma.
Screening and after every 2 cycles of treatment until disease progression. At least 4 weeks after a patient demonstrates response.
No
Luz Hammershaimb, M.D.
Study Director
MedImmune LLC
United States: Food and Drug Administration
MI-CP095
NCT00066196
August 2003
June 2007
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
University of Pittsburgh Cancer Institute | Pittsburgh, Pennsylvania 15213 |
Boston Medical Center | Boston, Massachusetts 02118 |
Winship Cancer Institute of Emory University | Atlanta, Georgia 30322 |
Vanderbilt University Medical Center | Nashville, Tennessee 37232-2516 |
Pacific Shores Medical Group | Long Beach, California 90813 |
Saint Francis Memorial Hospital | San Francisco, California 94109 |
Thomas Jefferson University | Philadelphia, Pennsylvania 19107-6541 |
Providence Portland Medical Center | Portland, Oregon 97213-3635 |
Indiana University Medical Center | Indianapolis, Indiana 46202 |
Medical Group of North County | Vista, California 92083 |
Blumenthal Cancer Center | Charlotte, North Carolina 28203 |
Oncology Specialists, S.C. | Park Ridge, Illinois 60068 |
Cancer Institute Medical Group | Los Angeles, California 90025 |
University of Miami | Miami, Florida 33136 |
Yale University School Of Medicine | New Haven, Connecticut 06520 |
Indiana Oncology Hematology Consultants | Indianapolis, Indiana 46202 |
Mayo Clinic Arizona | Scottsdale, Arizona 85259 |
Johns Hopkins University - SKCC at Johns Hopkins | Lutherville, Maryland 21093 |
Kansas City Oncology & Hematology Group | Kansas City, Missouri 64131 |
The Melanoma Center of St. Louis | St. Louis, Missouri 63131 |
HemOnc Care, P.C. | Brooklyn, New York 11235 |
UNC-Chapel Hill | Chapel Hill, North Carolina 27599 |
The University of Texas, MD Anderson Cancer Center | Houston, Texas 77030 |
Discovery Alliance | Houston, Texas 77030 |